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Val M. Runge, MDAbstract: For magnetic resonance, the established class of intravenous contrast
media is the gadolinium-based contrast agents. In the 3 decades since initial ap-
proval, these have proven in general to be very safe for human administration.
However, in 2006, a devastating late adverse reaction to administration of the less
stable gadolinium-based contrast agents was identified, nephrogenic systemic fi-
brosis. The result of actions taken by the EuropeanMedicines Agency and theUS
Food and Drug Administration, stratifying the agents by risk and contraindicating
specific agents in severe renal dysfunction, has led to no new cases being identi-
fied in North America or Europe. Subsequently, in 2014, long-term deposition in
the brain of gadolinium was first shown, after administration of 2 nonionic linear
chelates, gadodiamide, and gadopentetate dimeglumine. This has led to an in-
tense focus on the question of in vivo distribution, possible dechelation, and sub-
sequent deposition of gadolinium, together with substantial clarification of the
phenomenon as well as stratification of the agents on this basis. This review fo-
cuses on 8 critical questions regarding gadolinium deposition in the brain and
body, with the answers and discussion therein important for future regulatory de-
cisions and clinical practice. It is now clear that dechelation of gadolinium occurs
in vivo with the linear agents and is responsible for this phenomenon, with key
experts in the field recommending, except where there is no suitable alternative,
a shift in clinical practice from the linear to macrocyclic agents. In addition, on
March 10, 2017, the Pharmacovigilance and Risk Assessment Committee of
the EuropeanMedicines Agency recommended suspension of themarketing autho-
rization for 4 linear gadolinium contrast agents—specifically Omniscan, Optimark,
Magnevist, and MultiHance (gadodiamide, gadoversetamide, gadopentetate
dimeglumine, and gadobenate dimeglumine)—for intravenous injection. Cited
in the report was convincing evidence of gadolinium deposition in the brain
months after injection of these linear agents. Primovist/Eovist (gadoxetic acid
disodium) will remain available, being used at a lower dose for liver imaging, be-
cause it meets an important diagnostic need. In addition, a formulation of
Magnevist for intra-articular injection will remain available because of its very
low gadolinium concentration.
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T he approved gadolinium-based contrast agents (GBCAs) can bedifferentiated on the basis of structure (ligand type, specifically
macrocyclic vs linear) and charge, as detailed in Table 1.1–13 Stability
both in in vitro and in vivo, relative to the release of gadolinium (which
depends upon both thermodynamic and kinetic stability), has been
shown to be markedly superior for the macrocyclic agents when com-
pared with the linear agents.14–17 The linear nonionic agents (specifi-
cally gadodiamide and gadoversetamide) are also markedly less stable
by this measure than the linear ionic ones.18 All GBCAs cause, in a
small percent of patients, mild adverse reactions, including nausea
and hives, with a large number of articles in the scientific literature de-
bating the relative percent of such with the different agents.19 Severe
anaphylactic reactions can also occur with any of the agents, although
these are very rare.20
The market for the GBCAs in Europe today is similar in size to
that in the United States, with Japan being substantially smaller. The to-
tal for all 3 areas, in terms of gross sales, is in the range of half a billion
dollars. More than 40 million enhanced magnetic resonance scans are
performed worldwide each year. The macrocyclic agents dominate the
market, with the highest utilization in Europe where it is more than
80%. Overall, among the major manufacturers, Bayer has the largest
market share, whereas GE Healthcare has the smallest. In Europe, spe-
cifically, Guerbet has the largest market share, whereas in the United
States, this is held by Bayer. The 7 primary agents (Table 1) are
approved in all 3 of the major markets, with the exception of gadobenate
dimeglumine, which is not approved in Japan (source: Arlington Medical
Resources, Inc, https://decisionresourcesgroup.com).
Discussing individual agents, the market share for gadodiamide
(GE Healthcare) is substantially lower today than in the past—
particularly in Europe and the United States, presumably due to both
the impact of nephrogenic systemic fibrosis (NSF) and the issue of gad-
olinium deposition in the brain. Its current market share in the United
States is thought to be below 10%.
Being a late entrant into the field in the United States, gadoterate
meglumine (Guerbet) has currently only a small market share there.
This will significantly change when gadoversetamide sites are shifted
to gadoterate meglumine, which is anticipated (due to the late 2015 pur-
chase by Guerbet of Mallinckrodt's contrast media business). The mar-
ket share for gadobenate dimeglumine (Bracco) has risen substantially
in the last few years in the United States, with this agent benefiting as
a result of the falling market share of gadodiamide. In the early years
after its approval in the United States, gadoteridol (Bracco) reached a
market share near 25%, falling in subsequent years to low single digits,
in part due to the loss of a large distribution contract. The market share
today of this macrocyclic agent in the United States, which is rising, is
thought to be approximately 5%.www.investigativeradiology.com 317
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TABLE 1. Clinically Approved GBCAs in Worldwide Use—Names, Structure, and Occurrence of Dentate Nucleus Hyperintensity
Generic Name*† Trade Name Acronym Structure, Charge Dentate Nucleus Hyperintensity‡ No Dentate Hyperintensity‡
Gadopentetate dimeglumine Magnevist Gd-DTPA Linear, ionic Kanda et al,1 Radbruch et al2
Gadoterate meglumine Dotarem Gd-DOTA Macrocyclic Radbruch et al,2 Eisele et al3
Gadoteridol ProHance Gd-HP-DO3A Macrocyclic Kanda et al4
Gadodiamide Omniscan Gd-DTPA-BMA Linear, nonionic Kanda et al,1 Errante et al,5
McDonald et al,6 Quattrocchi et al7
Gadobutrol Gadovist (Gadavist) Gd-DO3A-butrol Macrocyclic Radbruch et al,8 Cao et al9
Gadobenate dimeglumine MultiHance Gd-BOPTA Linear, ionic Weberling et al,10 Ramalho et al11
Gadoxetic acid disodium Primovist (Eovist) Gd-EOB-DTPA Linear, ionic Kahn et al13 Ichikawa et al12§
*Listed in order of initial clinical approval.
†Gadoversetamide (Optimark, Gd-DTPA-BMEA) is not listed, as its use is being substituted by gadoterate meglumine.
‡Primary author listed for confirming report, with reference provided in parentheses.
§Study limited due to applied dose.
GBCA indicates gadolinium-based contrast agent.
Runge Investigative Radiology • Volume 52, Number 6, June 2017The focus of this review is to discuss gadolinium deposition in
the brain and body,21 examining 8 key issues, which cover the status
of current knowledge, further evaluations that need to be pursued,
and the potential impact of these on regulatory approval and use of
the GBCAs. It is well established today which of the agents causeFIGURE 1. Unenhanced axial T1-weighted images through the level of the de
dimeglumine, (B) 9 prior injections of gadobenate dimeglumine, (C) 6 prior in
meglumine. Hyperintensity of the dentate nucleus (arrows) is seen as a residu
dimeglumine and gadobenate dimeglumine, but not after (C and D) the macr
obtained before any contrast administrations (not shown) were normal in all 4
318 www.investigativeradiology.com
Copyright © 2017 Wolters Kluwer Hhyperintensity of the dentate nucleus (on unenhanced T1-weighted
magnetic resonance (MR) scans, after multiple prior administrations),
which parallels their in vitro and in vivo stabilities. This is detailed in
Table 1, with an example provided in Figure 1, and will not be dis-
cussed in detail further.ntate nucleus in patients having (A) 14 prior injections of gadopentetate
jections of gadobutrol, and (D) 10 prior injections of gadoterate
al after multiple injections of (A and B) the linear agents gadopentetate
ocyclic agents gadobutrol and gadoterate meglumine. Baseline images
patients. Images courtesy of Alexander Radbruch.
© 2017 Wolters Kluwer Health, Inc. All rights reserved.
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in the Brain
Although there are suggestions in the literature that patient
symptoms may be associated with or attributed to the administration
of GBCAs, specifically in regard to brain deposition of gadolinium,
no definitive such studies have yet been published. Two studies that
have drawn substantial attention, specifically the studies of Semelka
et al22 and Burke et al,23 are based solely on responses to surveys
(eliciting symptoms) provided to individuals who believe that they have
symptoms (selection bias), and thus do not allow for any scientific con-
clusions to be drawn. In both, the data were self-reported, unconfirmed
medically, and not linked to imaging or histology results. Welk et al24
evaluated retrospectively the possibility that GBCA exposure could
cause symptoms of parkinsonism. This is an important area for evalua-
tion, given the involvement of the substantial nigra and the associated
signaling to the globus pallidus in that disease. The study used multiple
administrative databases and analyzed more than 200,000 patients. The
incidence of parkinsonism without and with GBCA administration was
comparable. This study, with its inherent limitations, provides some re-
assurance that gadolinium deposition in the globus pallidus does not
lead to neuronal damage, which manifests itself as parkinsonism. How-
ever, baseline symptomatology of patients in possible retrospective
studies (eg, parkinsonism, brain tumors) is often severe, and subtle cer-
ebellar signs might easily escape detection. Evaluation of pharmaco-
vigilance databases by the 4 major producers of GBCAs worldwide
does not reveal reports of any chronic symptoms with sufficient scien-
tific evidence to suggest a causal association. One area that needs spe-
cific evaluation, however, is the possible risk of repeated linear GBCA
injections in patients receiving drugs that are neurotoxic to the dentate
nucleus. Metronidazole, a common antibacterial and antiprotozoal
agent, is known to have neurologic toxicity with a predilection for the
dentate nucleus, with signal changes onMR imaging seen in the dentate
and red nuclei.25
Accumulation of Gadolinium in Tissues Other
Than the Brain
Clinical data regarding gadolinium deposition in tissues other
than the brain after GBCA administration are limited. An important les-
son from the NSF experience is the difficulty in ascertaining with cer-
tainty the specific contrast media and number of administrations that
any specific patient may have been given. Health care providers have
access to data only within their own system, typically, with patients of-
ten crossing between providers. Patients also do not reliably know
whether an examination was performed with a contrast agent or not,
or even whether the examination was MR as opposed to CT. Most cer-
tainly patients in general do not know the specific contrast agent used,
and there is no definitive medical record in existence that provides
this information.
It should be stressed that, to date, the form of gadolinium, other
than in the brain, has rarely been investigated. This could be as the intact
chelate, or dissociated and soluble (presumably bound to a macromole-
cule), or precipitated. These will neither behave similarly in the body
nor have similar interactionswith important structures such as ion chan-
nels, which control the flow of ions across the cell membrane.
Care needs also to be exercised, in evaluating tissue deposition of
gadolinium, relative to the time interval between the last contrast ad-
ministration and tissue collection. This is important in any study
attempting to differentiate between the different agents, given the tem-
poral elimination of the agents. An example is the study by Murata
et al.26 Study limitations, acknowledged by the authors, include a lack
of control for confounding factors, including specifically prior exposure
to other GBCAs, and the varying time between contrast administration
and tissue sampling. Looking at the time between the last contrast agent
administration and death (tissue sampling), this varied between 5 and© 2017 Wolters Kluwer Health, Inc. All rights reserved.
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ing factors, should be viewed with caution. These difficulties lead to
the conclusion that such fundamental questions are best addressed in
preclinical studies, which allow for control of all potential confounders.
Lancelot recently published a meta-analysis from preclinical and
clinical pharmacokinetic data concerning gadolinium in blood, urine,
and bone.27 This work confirmed the existence of prolonged excretion
of gadolinium after contrast administration, specifically a residual ex-
cretion phase much slower than the conventional elimination phase.
This is indirect evidence of a deep compartment of distribution for gad-
olinium in the body after contrast administration. The slopes of the re-
sidual excretion phase highly correlated with thermodynamic stability
constants. The data suggest that stability of the GBCA influences the
residence time in this deep compartment. Much higher bone clearance
rates were determined for the macrocyclic as compared with the linear
GBCAs, translating into a much shorter bone half-life. The difference
in bone clearance between 14C- and 153Gd-labeled agents further sup-
ports that macrocyclic agents are cleared by slow washout like any inert
small molecule, without biochemical transformation, whereas the linear
GBCAs undergo disassociation and deposition. The gadolinium depos-
ited in the bone by a linear agent could later be mobilized and released
back into the blood, with bone thus serving as a reservoir. In addition
to these findings regarding differences in the clearance of the GBCAs,
the quantities of gadolinium measured in the skin, bone, and brain are
much lower with the macrocyclic GBCAs. Thus, distinguishing be-
tween linear and macrocyclic GBCAs, a difference is noted regarding
both the quantity of the gadolinium present in tissues as well as the rate
of wash out.
Gadolinium is a lanthanide metal (atomic number 64), 1 of 15
such elements with atomic numbers 57 (lanthanum) to 71 (lutetium).
For metals in general, the skeleton is a target organ, with bioaccumula-
tion therein, either for storage of useful elements or protection against
toxic ones.28 There is limited toxicologic information available regard-
ing accumulation in the body of lanthanides. Of note, Fosrenol (lantha-
num carbonate) is commonly prescribed (oral administration) to reduce
serum phosphate in end-stage renal disease patients. Possible adverse
effects have been investigated in this population, with no evidence of
bone toxicity.29 Despite progressive accumulation of lanthanum in
bone, no clinical symptoms possibly related to toxic effects have been
noted.30 At this time, no conclusive evidence exists in the scientific lit-
erature to show neurotoxicity with other lanthanide elements.
Recent Animal Investigations
Three early animal investigations were crucial in improving our
understanding of gadolinium deposition in the brain.31–33 After repeated
administration of linear GBCAs (specifically gadobenate dimeglumine,
gadopentetate dimeglumine, and gadodiamide), progressive T1 signal
hyperintensity in the rat equivalent of the dentate nucleus was demon-
strated, with deposition of gadolinium confirmed in the tissue. This
was in distinction to the macrocyclic GBCAs (specifically gadoterate
meglumine and gadobutrol) for which no effect was observed. This
work was performed by 2 of the major 4 manufacturers of GBCAs.
Given the lack of published work from the other 2 manufacturers dis-
puting these findings, it is highly likely that this work has been inter-
nally confirmed by both.
Several additional important animal studies have been published
in the last year, providing further clarification. In renally impaired rats,
when compared with rats with normal renal function, gadolinium up-
take, after multiple injections of gadodiamide, was potentiated in the
cerebellum, brain, and bones.34 This study also showed that plasma
gadolinium was predominately in a disassociated, soluble form. Total
Gd concentration in the brain correlatedwith renal function. Translating
these results to clinical practice, concern is raised due to the substantial
population of patients with moderate renal failure. The data in this studywww.investigativeradiology.com 319
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Runge Investigative Radiology • Volume 52, Number 6, June 2017suggest that moderate renal failure increases the risk of Gd uptake in the
brain and other tissues, advocating a special warning for gadodiamide,
as well as potentially all the linear agents, for this patient population.
Given similarities in stability and potential for dechelation, these results
would also be expected with gadoversetamide.
Research from GE Healthcare has further confirmed the dose-
dependent deposition of gadolinium in the rat brain after gadodiamide
administration.35 Evaluation of low- and high-dose groups indicated
that the uptake mechanisms were not saturated (greater deposition oc-
curred at higher doses). Quantitative measures revealed partial clear-
ance (a decrease by about half ) in comparison with the 1- and
20-week postdose groups. This long-term follow-up (20 weeks in the
rat) is comparable to 15 human years. Histologic evaluation of the brain,
limited only to hematoxylin-eosin stains, revealed no changes. A subse-
quent letter to the editor from neurology and neuropathology colleagues,
however, stated that normal-appearing hematoxylin-eosin–stained sec-
tionswould not exclude gadolinium-related neurotoxicity, and that such
an assessment should include lactate dehydrogenase immunoreactivity
or electron microscopy, in addition to quantitative measures of reactive
astrogliosis and microglial activation.36
In an additional study, after repeated high dosing in rats with
normal renal function, NSF like macroscopic and microscopic lesions
in the skin were only seen with gadodiamide.37 These were not seen
with gadopentetate dimeglumine and the 2 evaluated macrocyclic
GBCAs, gadobutrol and gadoteridol. No histologic changes were ob-
served with any agent in the brain. The gadolinium concentration in
the skin was determined to be highest with gadodiamide, with the rank
being gadodiamide >> gadopentetate dimeglumine >> gadobutrol =
gadoteridol, correlating well with the higher kinetic stability of the mac-
rocyclic agents. Gadolinium concentration in the brain ranked similarly
for the agents with the exception that gadodiamide = gadopentetate
dimeglumine. Laser ablation inductively coupled plasma mass spec-
trometry revealed high gadolinium concentrations in the deep cerebel-
lar nuclei and the granular layer of the cerebellar cortex with the
2 linear agents, but not with the macrocyclic agents. A similar distribu-
tion has recently been confirmed in a single human case report, using
laser ablation inductively coupled plasma mass spectrometry, after
4 doses of linear GBCAs.38
Further evidence supporting the stability and excretion ofmacro-
cyclic agents is provided by juvenile rat (those with immature renal
function) toxicologic investigations pursued just before the knowledge
emerged concerning gadolinium deposition by linear agents in the
brain.39,40 The first study evaluated only gadoterate meglumine and in-
volved both single and multiple administrations. Total Gd concentra-
tions were similar in all tissues whether after single or repeated
dosing, with only trace amounts of gadolinium quantifiable at the end
of the treatment-free period, almost exclusively in the kidneys. In the
second study, repeated administrations of gadoteric acid were shown
to be well tolerated, despite the immature renal function. In distinction,
gadodiamide, which was also evaluated, induced significant mortality
(4 of 14 rats) and morbidity. Alopecia, hyperpigmentation, and severe
dermal and epidermal lesions were seen after gadodiamide administra-
tion. Higher tissue concentrations of gadolinium were also found with
gadodiamide as compared with gadoteric acid, and dissociation of
gadodiamide was noted to be present in skin and liver.
The most recent animal study assessed and quantified the chem-
ical form of residual gadolinium in the brain after repeated dosing in
rats with normal renal function.15 For all 3 linear agents evaluated—
gadodiamide, gadopentetate dimeglumine, and gadobenate dimeglumine—
the residual Gd was present in at least 3 distinctive forms—soluble
small molecules (likely the intact chelate), soluble macromolecules,
and insoluble Gd, with no relevant differences between these agents.
The authors hypothesized that the latter 2 forms were most likely re-
sponsible for the residual T1 high signal intensity seen in clinical pa-
tients in the dentate nucleus and other structures. Gd concentrations320 www.investigativeradiology.com
Copyright © 2017 Wolters Kluwer Hin the brain with the macrocyclic agents evaluated—gadobutrol and
gadoterate meglumine—were substantially lower, with the Gd only
present as soluble small molecules. This work again emphasizes the ki-
netic inertness of the macrocyclic agents and its crucial importance in
prevention of release of Gd in the brain as compared with the linear, ki-
netically less restricted, GBCAs. The macrocyclic agents seem to be
still intact in brain tissue, whereas up to 27% of the fraction retained
in the brain with the linear agents evaluated seems to be present as mac-
romolecules, the result of dechelation.
Not yet well understood is how the GBCAs reach the brain,
given that they do not cross the intact blood-brain barrier. However, re-
cent data, not yet replicated in animals, show that intrathecal injection of
a GBCA leads to T1 signal hyperintensity of the dentate nucleus and
globus pallidus, suggesting entry via the glymphatic system, which is
a brain-wide cerebrospinal fluid (CSF)-interstitial fluid mechanism by
which interstitial solutes are cleared.41 That CSF is a potential pathway
of GBCA entry into the brain was confirmed in a recent animal study by
Jost et al.42 No differences in penetration and distribution into the CSF
was noted between the 6 evaluated, marketed GBCAs.
Gadolinium in the Environment
Gadolinium is today found in nature, as a result of the impact of
its use by humans (anthropogenic gadolinium).43 It has been reported in
rivers, lakes, groundwater, and tap water worldwide. The anthropogenic
Gd found is dominated by highly stable, water-soluble complexes, spe-
cifically GBCAs administered forMR imaging and subsequently found
in waste water (ultimately passing through sewage treatments plants
into surface water).44 In evaluating the potential for adverse effects with
human exposure to gadolinium in tap water, it should be noted that the
systemic bioavailability after oral exposure is minimal. There is no ev-
idence to date for substantial systematic exposure of humans to Gd on
the basis of uptake from the environment.
The effects of UV radiation on the GBCAs were recently in-
vestigated because these agents would be exposed to UV when pres-
ent as anthropogenic gadolinium and because of the increasing use
of UV irradiation in wastewater treatment processes. Four agents were
evaluated. Gadopentetate dimeglumine, gadobutrol, and gadoterate
meglumine all showed high stability in irradiation experiments, with
gadobenate dimeglumine degrading, yielding by-products and
dissociated gadolinium.45
Minimizing Risk
Gadolinium-based contrast agents should only be administered
if the information so provided is necessary, and specifically expected
to increase the confidence in correct disease diagnosis or assessment
thereof, or disease exclusion. No GBCAs are approved for central ner-
vous system (CNS) or body indications (excluding the liver) at lower
than standard dose, specifically 0.1 mmol/kg. Indeed, in the case of
gadobenate dimeglumine, the application to the Food and Drug Admin-
istration (FDA) for approval of half dose (0.05 mmol/kg) for the CNS
was rejected in years past, despite the higher relaxivity, presumably
due to a lack of comparable efficacy. Similarly, the attempt to receive
approval by the FDA for half dose gadopentetate dimeglumine in young
children, potentially reducing the contrast burden in this vulnerable
population, failed. Approved dose translates to the recommended low-
est effective dose, with health care providers advised not to decrease
dose due to the potential lack of efficacy. As with any injection, subse-
quent repeated injections of a GBCA should only be performed after
careful individual patient evaluation of benefit versus risk.
Two patient groups are potentially at higher risk for gadolinium
deposition in the brain after administration of GBCAs. Renal impair-
ment leads to longer exposure times to the administered dose, increas-
ing gadolinium deposition in tissue, and specifically in the brain for
the linear chelates. Patients with chronic disease may have repeated© 2017 Wolters Kluwer Health, Inc. All rights reserved.
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deposition. T1-weighted hyperintensity in the dentate nucleus has been
shown recently to occur at lower cumulative doses of linear agents in
patients on dialysis than in prior studies of patients with normal renal
function.46 Evidence—from both clinical and preclinical studies—to
date favors that patients with impaired renal function are at higher risk
for gadolinium accumulation in the brain and in bone, with this conclu-
sion applying only to the group of agents that have such gadolinium de-
position, the linear chelates.34 Both cited studies furthermore noted
deposition of gadolinium in the choroid plexus (beyond what was pre-
viously established, specifically the dentate nucleus and the globus
pallidus). The Cornell and Columbia groups subsequently published a
study of patients receiving 35 or more linear GBCA administrations
with normal renal function. Increased signal intensity on unenhanced
T1-weighted images, presumed to be due to gadolinium deposition,
was much more extensive anatomically than previously described, be-
ing seen also in the posterior thalamus, red nucleus, substantia nigra,
cerebellar peduncle, and colliculi.47
Suitable Alternatives
No suitable alternatives currently exist for CNS and body MR
imaging relative to the use of the extracellular renally excreted GBCAs.
The data previously presented support use of the macrocyclic agents as
opposed to the linear agents.
Two GBCAs have specific liver approval, and although both are
linear agents, the hepatocyte uptake provides in delayed imaging addi-
tional information for lesion characterization and detection. These 2
agents differ according to administered dose and the timing of imaging
for the hepatocyte selective phase. Consideration of in vitro stability
studies,14 degree of liver enhancement, quantity of administered gado-
linium (1/4 for gadoxetate disodium when compared with the other
GBCAs, because it is formulated at 0.25 mmol/mL and administered
at 0.1 mL/kg), and ease of obtaining delayed images (within 10–20 vs
60–90 minutes) all favor 1 agent, gadoxetate disodium, if other alterna-
tives are not available.
Designs for Future Nonclinical Studies
Further work is needed to identify and characterize the nature of
the gadolinium binding macromolecules (with high molecular weight)
as well as the insoluble fraction, detected after injection in animals of
the linear chelates. It is important to confirm as well that the small sol-
uble molecules detected represent intact GBCA. This work would log-
ically follow that described in the third section of this review describing
recent animal investigations.
In-depth histopathology studies are indicated beyond traditional
light microscopy and stains. Possible more specific markers include
glial fibrillary acidic protein and ionized calcium binding adaptor mol-
ecule 1 (a microglia/macrophage-specific calcium-binding protein).
Magnetic resonance spectroscopy might also be of value to assess brain
metabolism and the possible effect of repeated injections of linear
GBCAs in suitable rat models.
The numerous advantages associated with nonclinical models
should be acknowledged, for example, their prospective nature, the pos-
sibility of euthanasia at study completion with in-depth tissue analysis,
and the large number of potential validated end points. Furthermore, rat
models are considered very translational with respect to the study of
neurologic deficits, specifically including akinesia, tremor, postural
deficits, and dyskinesia.48,49
Animal investigations would thus be important to assess poten-
tial neurologic effects of gadolinium deposition in the brain. Motor co-
ordination function (and thus specifically involvement of the dentate
nucleus) can be evaluated with standard tests including balancing on a
rotating rod (the rotarod test) and an analysis of gait. Additional estab-
lished behavioral animal tests that assess partially cognitive function© 2017 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2017 Wolters Kluwer Hinclude the open-field test (which assesses motor activity and reactivity
to a novel environment), the water maze test (which evaluates learning
and memory), grooming analysis, and eye blink conditioning. For 1
macrocyclic agent, gadoteratemeglumine, such behavioral tests (specif-
ically the water maze and open field) have been performed in juvenile
rats after both single and repeated contrast administrations, and did
not show any change.39
Intracellular metabolic, neurofunctional, and neuromorpholo-
gical biomarkers should also be investigated through in vitro and in vivo
models. These approaches could potentially detect not only neurotoxic
but also neuromodulator effects caused by gadolinium deposition in the
brain. Because the brain has permanent active retrocontrol loops, gado-
linium deposition could subtly influence some intracellular, synaptic,
axonal, neurochemical, or neuroelectrical biomarkers.
Options for Clinical Studies
There are many challenges for clinical trials, whether prospective,
retrospective, or involving data from large registries, to determine if gad-
olinium deposition in the brain has any clinical relevance or is associated
with any adverse health effects. The greatest challenge is that no clear, de-
finitive end points have been identified. One of the most important pri-
mary end points would be symptomatology involving a function
controlled by the affected basal ganglia, yet, to date, no such correlated
symptom has been identified. The basal ganglia involved control many
different motor and cognitive processes, which are also involved bymany
CNS diseases and therapeutic drugs. An additional major challenge is se-
lection of a suitable patient population. Patients are needed who have
been or will be subject to many repeat contrast-enhanced MR scans
due to their disease process, such as multiple sclerosis or primary brain
tumors. Unfortunately, the overlap in potential symptomatology with
the primary disease of the patient and drugs used for treatment limits
options in these populations. Outside of the CNS, the most obvious
population with repeated MR studies is that of patients undergoing
screening for breast cancer. Performance of clinical studies in this pa-
tient population unfortunately raises ethical questions.
Prerequisites for an ideal study include documentation of a nor-
mal baseline, including a thorough neurologic examination with cogni-
tive function testing, an adequate control group, and exclusion of prior
GBCA exposure. Using a prospective design, it would unfortunately
take many years to obtain reliable information, given the need for mul-
tiple exposures to a GBCA over time.
The large electronic available databases do offer the possibility
of retrospective studies, and in the “big data” era, it could reveal weak,
subsymptomatic, and chronic clinical signs. Retrospective studies and
those involving large registries are limited, however, in 2 important
ways. First, no baseline neurologic or cognitive testing can be per-
formed. Second, the specific GBCAs administered typically cannot be
identified with confidence. It would be important for any such study
to identify patients exposed to 1 and only 1 GBCA, avoiding possible
carryover effects from previous administration of other agents.CONCLUSIONS
An unstated question that is critical to the analysis of the GBCA
data, specifically for each of the linear agents, is whether there are pa-
tient populations or indications for which there are no suitable alterna-
tives. Clearly, there are alternatives to the majority of these agents.
The end result in terms of the actions by the regulatory authorities,
and specifically the FDA and European Medicines Agency (EMA), is
likely to be based upon a combination of science, politics, and possible
legal action.
In the last decade, due to NSF and the evolving knowledge con-
cerning gadolinium deposition in the brain, there has been a dramatic
shift in market share for the 4 major manufacturers involved—Bayer,
Guerbet, Bracco, and General Electric. These sales figures, however,www.investigativeradiology.com 321
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gadopentetate dimeglumine has fallen substantially, with Bayer sub-
stituting gadobutrol (a macrocyclic agent) for gadopentetate dimeglumine
(a linear agent). Given Guerbet's acquisition of Mallinckrodt's contrast
media business in late 2015, the replacement of gadoversetamide (a
linear agent similar in structure to gadodiamide) by gadoterate
meglumine (a macrocyclic agent) is anticipated. In addition, in early
2017, at the European Congress of Radiology, GE Healthcare an-
nounced that it would launch in Europe an ionic macrocyclic agent,
“gadoteric acid.” Movements by region of the world in terms of spe-
cific contrast agent use have been substantially different, with the
greatest changes as well as level of concern by patients and physicians
being in Europe. Of the world's regulatory agencies, the EMA has been
the most progressive in dealing with this latest issue, similar to how this
agency dealt with NSF.
After a year-long consideration of the latest issue (gadolinium
deposition in the brain and body), including many meetings, 4 rounds
of questions from the EMA to industry with responses, and an ad hoc
expert group meeting, the Pharmacovigilance and Risk Assessment
Committee concluded it's assessment of the gadolinium agents and,
on March 10, 2017, recommended the following regulatory action:
Suspension of the marketing authorization of 4 linear GBCAs
(gadodiamide, gadoversetamide, gadopentetate dimeglumine, and
gadobenate dimeglumine) was advised, which would leave—of the lin-
ear agents—only gadoxetic acid on the market for liver scans and a for-
mulation of gadopentetic acid for joint injections. Approval for the
macrocyclic agents was left unchanged; this recommendation was sent
to the Committee for Medicinal Products for Human Use of the EMA,
which—barring action by the companies concerned to request the
Pharmacovigilance and Risk Assessment Committee to re-examine its
recommendations—will adopt the Agency's opinion at 1 of its meet-
ings in 1 to 2 months. The final stage of review is the adoption by the
European Commission of a decision, applicable and legally binding,
for all European Union Member States.
Given the concern with gadolinium deposition, use of exclu-
sively the macrocyclic agents is advocated for CNS and body imaging.
Two agents exist with hepatobiliary properties, with both linear in na-
ture. This clinical application is important, suggesting that continued
approval of 1—logically that with the lowest gadolinium dose and
greatest utility—be maintained. Despite that hepatobiliary agents are
less likely to be used in any single patient with an extreme number of
doses, development of macrocyclic hepatobiliary agents is also advo-
cated. These were pursued in the past,50,51 with clinical approval not
sought due to changing market and company dynamics at that time.
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